Loading stock data…
$42.71+0.33 (+0.78%)
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Ionis Pharmaceuticals, Inc. in the Healthcare sector is trading at $42.38 with a market capitalization of $9.4B. Wall Street consensus targets $83.64 (22 analysts), implying a +97.3% move over the next 12 months. The stock is currently near its 52-week low of $42.36, remaining 38.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $267.95M↑ | $246.09M↑ | $203.33M↑ | $156.72M↓ | $452.05M |
| Gross Profit | $265.21M↑ | $243.09M↑ | $195.37M↑ | $154.38M↓ | $447.90M |
| Operating Income | -$102.30M↑ | -$117.48M↑ | -$214.47M↓ | -$160.17M↓ | $139.84M |
| Net Income | -$114.65M↓ | -$92.53M↑ | -$229.39M↓ | -$128.61M↓ | $123.55M |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...